CIDEC and Parkinson disease: The majority (89%) of these randomly selected DEGs in 3xTg-AD mice (Figure 1A, Supplementary Table 1) did not appear as DEGs for wild-type mice (Figure 1B, Supplementary Table 2) including those for Parkinson's (e.g., Tox3, Pak6, and Gucy2c) and Huntington's (e.g., Tgm1 and Fam171b) pathology, aging (e.g., Abcc9 and Postn), potential destruction of the blood brain barrier (Jam3), vascular remodeling (e.g., EphB4 and Angptl6), lipid disorders (e.g., Acat3 and Cidec), and inflammation (e.g., Alox8).